MedPath

Effectiveness Of HDtDCS In Cognitive And Negative Symptoms Of Schizophrenia measured Using fMRI

Phase 3
Conditions
Health Condition 1: F20- Schizophrenia
Registration Number
CTRI/2021/07/034759
Lead Sponsor
Central Institute Of Psychiatry
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1.Diagnosis of Schizophrenia using Diagnostic Criteria for Research (DCR) of International Classification of Disease-10th edition (ICD-10, World Health Organization,1992)

2.Duration of illness to be more than or equal to two years.

3.Age between 18- 60 years of either sex

4.The Positive and Negative Syndrome Scale for Schizophrenia (PANSS) negative symptoms score of more than 15

5.Scale for Assessment of Negative Symptoms (SANS) score more than 20

6.Right-handed

7.Educated upto class VIII or above

8.Patients giving written informed consent.

Exclusion Criteria

1.Presence of co-morbid neurological or other psychiatric disorder(s).

2.Patient with co morbid substance dependence, except nicotine and caffeine.

3.Having any metallic implants/parts in body

4.Subjects who have received ECT in past 6 months.

5.Colour blind

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Reduction in scores on negative and cognitive symptoms after application of HDtDCS.Timepoint: 1. At baseline <br/ ><br>2. At the end of 2 weeks <br/ ><br>3. At the end of 4 weeks
Secondary Outcome Measures
NameTimeMethod
Change in fMRI activation of Pre Frontal Cortex using cognitive task and change in resting state functional connectivity at baseline and after application of HDtDCS.Timepoint: 1. At baseline <br/ ><br>2. At the end of 2 weeks
© Copyright 2025. All Rights Reserved by MedPath